| Identification | Back Directory | [Name]
Agomelatine-d3 (acetamide-2,2,2-d3) | [CAS]
1079389-38-0 | [Synonyms]
Agomelatine-d3 (acetamide-2,2,2-d3)
Agomelatine-D3 (acetamide-2,2,2-D3)Q: What is
Agomelatine-D3 (acetamide-2,2,2-D3) Q: What is the CAS Number of
Agomelatine-D3 (acetamide-2,2,2-D3) | [Molecular Formula]
C15H17NO2 | [MDL Number]
MFCD28902049 | [MOL File]
1079389-38-0.mol | [Molecular Weight]
243.31 |
| Hazard Information | Back Directory | [Uses]
Agomelatine-d3 is the deuterium labeled Agomelatine. Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively[1]. Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively[2]. | [IC 50]
MT2; MT1 | [References]
[1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:10.1177/1060028018797110
[2] Audinot V, et al. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jun;367(6):553-61. DOI:10.1007/s00210-003-0751-2
[3] Millan MJ, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003 Sep;306(3):954-64. DOI:10.1124/jpet.103.051797
[4] Aguiar CC, et al. Effects of agomelatine on oxidative stress in the brain of mice after chemically induced seizures. Cell Mol Neurobiol. 2013 Aug;33(6):825-35. DOI:10.1007/s10571-013-9949-0 |
|
|